JMP Securities Initiates Coverage on Artivion (NYSE:AORT)

JMP Securities started coverage on shares of Artivion (NYSE:AORT - Free Report) in a research report sent to investors on Wednesday, MarketBeat.com reports. The brokerage issued an outperform rating and a $33.00 price target on the stock.

Other research analysts have also recently issued reports about the stock. Lake Street Capital raised their price objective on shares of Artivion from $28.00 to $30.00 and gave the stock a "buy" rating in a research note on Tuesday, July 2nd. Needham & Company LLC restated a "buy" rating and set a $30.00 target price on shares of Artivion in a research report on Friday, September 27th. Oppenheimer raised their target price on shares of Artivion from $25.00 to $30.00 and gave the stock an "outperform" rating in a research report on Friday, August 9th. Finally, Stifel Nicolaus raised their target price on shares of Artivion from $28.00 to $30.00 and gave the stock a "buy" rating in a research report on Friday, September 13th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Artivion presently has a consensus rating of "Buy" and an average target price of $30.60.

Artivion Price Performance

Artivion stock traded up $0.33 during mid-day trading on Wednesday, reaching $26.86. The company had a trading volume of 223,311 shares, compared to its average volume of 224,649. Artivion has a 1 year low of $12.16 and a 1 year high of $29.24. The company has a debt-to-equity ratio of 1.07, a current ratio of 5.63 and a quick ratio of 4.04. The company has a market capitalization of $1.12 billion, a P/E ratio of -110.54 and a beta of 1.74. The stock's 50-day simple moving average is $25.80 and its 200-day simple moving average is $24.58.

Artivion (NYSE:AORT - Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The company reported $0.07 earnings per share for the quarter, topping analysts' consensus estimates of $0.03 by $0.04. Artivion had a negative net margin of 2.22% and a positive return on equity of 3.81%. The business had revenue of $98.02 million during the quarter, compared to analysts' expectations of $97.70 million. On average, equities analysts predict that Artivion will post 0.2 EPS for the current year.

Insider Activity at Artivion

In related news, SVP Jean F. Holloway sold 3,167 shares of Artivion stock in a transaction on Monday, August 26th. The shares were sold at an average price of $26.55, for a total transaction of $84,083.85. Following the transaction, the senior vice president now owns 161,932 shares in the company, valued at approximately $4,299,294.60. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, SVP Jean F. Holloway sold 3,167 shares of Artivion stock in a transaction on Monday, August 26th. The shares were sold at an average price of $26.55, for a total transaction of $84,083.85. Following the sale, the senior vice president now owns 161,932 shares of the company's stock, valued at $4,299,294.60. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Jean F. Holloway sold 2,383 shares of Artivion stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $25.76, for a total transaction of $61,386.08. Following the sale, the senior vice president now directly owns 165,099 shares in the company, valued at $4,252,950.24. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 37,109 shares of company stock worth $951,935. 8.10% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Artivion

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Creative Planning increased its position in shares of Artivion by 182.1% in the 3rd quarter. Creative Planning now owns 28,635 shares of the company's stock worth $762,000 after purchasing an additional 18,486 shares during the last quarter. SG Americas Securities LLC bought a new stake in shares of Artivion in the 3rd quarter worth about $450,000. Perceptive Advisors LLC increased its position in shares of Artivion by 4.7% in the 2nd quarter. Perceptive Advisors LLC now owns 2,793,703 shares of the company's stock worth $71,658,000 after purchasing an additional 124,725 shares during the last quarter. The Manufacturers Life Insurance Company increased its position in shares of Artivion by 3.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,301 shares of the company's stock worth $392,000 after purchasing an additional 481 shares during the last quarter. Finally, Marshall Wace LLP bought a new stake in shares of Artivion in the 2nd quarter worth about $366,000. Hedge funds and other institutional investors own 86.37% of the company's stock.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.